Descripción de la empresa
Assertio Holdings, Inc. operates within the healthcare sector as a specialized manufacturer of pharmaceutical products, specifically focusing on the production and distribution of generic and specialty drugs for patients in the United States. The company's primary offering includes INDOCIN, an oral and suppository solution designed to treat moderate to severe rheumatoid arthritis, including acute flares of chronic disease and ankylosing spondylitis. This business model places the entity squarely in the Drug Manufacturers - Specialty & Generic industry, where revenue generation relies heavily on regulatory approvals, patent expirations, and market access rather than continuous product launches. The company currently maintains a market capitalization of $118.66M, generates annual revenue of $118.71M, and employs a workforce of 53 individuals. These valuation and operational metrics indicate that Assertio Holdings functions as a micro-cap enterprise with a revenue scale roughly equivalent to its market capitalization, suggesting a pricing structure where the market values the firm at a one-to-one ratio with its sales figures.
Salud financiera
The company reported a trailing twelve-month revenue of $118.71M, yet simultaneously posted a net income loss of $30,375,000 and an EBITDA of $12.78M, revealing a significant disparity between top-line sales and bottom-line profitability. This gap between positive revenue and negative net income highlights a cost structure where operating expenses, likely driven by research, development, and regulatory compliance costs, substantially exceed the gross profit generated from drug sales. Additionally, the firm generated negative free cash flow of $-16,582,250, which indicates that the company is currently burning cash and lacks the operational liquidity to fund growth or debt service without external financing. The margin analysis further underscores these financial pressures, with a gross margin of 70.2% indicating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -105.2% and a profit margin of -25.6%. Such negative operating and profit margins suggest that fixed costs and overhead are consuming all gross profits while adding to overall losses. On the balance sheet, the company holds $63.41M in cash against $40.25M in total debt, resulting in a debt-to-equity ratio of 42.84, which presents a highly leveraged profile despite the cash buffer. The current ratio stands at 1.70, providing a moderate cushion for short-term liquidity needs, yet the negative return on equity of -28.3% and negative return on assets of -3.9% reveal that management is currently unable to generate returns on shareholder capital or total assets.
Evaluación de valoración
Valuation metrics for Assertio Holdings present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is calculated at 2.56. The absence of a trailing P/E compared to the existence of a forward P/E implies that the market is pricing the stock based on anticipated future earnings recovery rather than historical profitability. The price-to-book ratio is recorded at 1.26, suggesting that the market values the company at a slight premium of 26% over its tangible book value. Supporting this valuation, the price-to-sales ratio is exactly 1.00, while the EV/EBITDA multiple sits at 7.47, indicating that the enterprise value relative to cash flows is priced conservatively for a pharmaceutical entity. In terms of trading range, the stock has a 52-week high of $20.45 and a 52-week low of $7.65, meaning the current price sits at the lower end of its recent trading history relative to the high. The beta value of 0.43 indicates that the stock exhibits low volatility, moving with significantly less intensity than the broader market and offering a lower-risk profile for investors seeking stability.
Growth & Income
Growth metrics reveal a challenging trajectory, with revenue growth year-over-year declining by 57.9%, while earnings growth is listed as N/A due to the current period losses. The contraction in revenue suggests a shrinking market share or a reduction in sales volume, whereas the lack of earnings growth data reinforces the company's current inability to scale profitability. Since the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders. Instead of paying dividends, the firm reinvests its limited resources or relies on cash reserves to sustain operations, though the negative free cash flow complicates this strategy. The overall growth and income profile for Assertio Holdings is characterized by significant revenue contraction, zero dividend income, and a reliance on future earnings potential to justify its current market valuation.